在本研究中,我们着手基于吡唑并[3,4- d ]嘧啶支架合理优化PKD抑制剂。本研究的先导化合物是 1-NM-PP1,我们和其他人之前发现它可以抑制 PKD。在我们的筛选中,我们鉴定出一种化合物 (3-IN-PP1),其效力比 1-NM-PP1 提高 10 倍,为对吡唑并显示敏感性的激酶的特定蛋白激酶抑制剂开辟了新的可能性[3,4- d ]嘧啶衍生的化合物。有趣的是,观察到的 SAR 与通常观察到的结合模式并不完全一致,其中吡唑并[3,4- d ]嘧啶化合物以与 PKD 天然配体 ATP 类似的方式结合。因此,我们建议采用另一种结合模式,其中化合物翻转 180 度。这种基于吡唑并[3,4- d ]嘧啶的化合物的可能的替代结合模式可以为用于对吡唑并[3,4- d ]嘧啶敏感的激酶的新型特异性蛋白激酶抑制剂铺平道路。
The present invention provides novel compounds that are antagonists of PI3 kinase, PI3 kinase and tryosine kinase, PI3Kinase and mTOR, or PI3Kinase, mTOR and tryosine kinase.
The present invention provides novel compounds that are antagonists of PI3 kinase, PI3 kinase and tyrosine kinase, PI3 kinase and mTOR, or PI33 kinase, mTOR and tyrosine kinase.
The present invention provides novel compounds that are antagonists of PI3 kinase, PI3 kinase and tyrosine kinase, PI3 kinase and mTOR, or PI33 kinase, mTOR and tyrosine kinase.
Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists
申请人:The Regents of the University of California
公开号:US07585868B2
公开(公告)日:2009-09-08
The present invention provides novel compounds that can be used as antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR. The present invention also provides methods of using the compounds for treating various disease conditions. The compounds include those having the formula:
wherein the R1, R2 and R36 are as defined herein.
Compounds and compositions are provided for treatment or amelioration of one or more disorders characterized by defects in protein trafficking. A method of treating a disorder characterized by impaired protein trafficking includes administering to a subject or contacting a cell with a compound of Formula I: [formula here] or pharmaceutically acceptable salts or derivatives thereof.